Acadia Pharmaceuticals (ACAD) Shares Outstanding (Weighted Average) (2010 - 2026)

Acadia Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $170.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 2.22% year-over-year to $170.5 million; the trailing twelve-month figure through Mar 2026 stood at $170.5 million (up 2.22% YoY), and the FY2025 full-year result was $168.4 million, up 1.59% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $170.5 million, up from $168.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $170.5 million in Q1 2026, with the low at $161443.0 in Q2 2022.
• Average Shares Outstanding (Weighted Average) over 5 years is $136.2 million, with a median of $164.2 million recorded in 2023.
• Year-over-year, Shares Outstanding (Weighted Average) sank 99.9% in 2024 and soared 101506.18% in 2025.
• Tracing ACAD's Shares Outstanding (Weighted Average) over 5 years: stood at $161.7 million in 2022, then advanced by 1.32% to $163.8 million in 2023, then grew by 1.16% to $165.7 million in 2024, then gained by 1.59% to $168.4 million in 2025, then grew by 1.28% to $170.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $170.5 million (Q1 2026), $168.4 million (Q4 2025), and $167.8 million (Q3 2025), per Business Quant data.

Peer Comparison